SU2C and Genentech announced a Catalyst collaboration aimed at accelerating the development of new cancer treatments and combination therapies by providing funding and access to a dozen of the company’s medicines.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
